R&D Story
GC Biopharma’s researchers
Continue to rise
To the challenge of saving lives.
Third-Generation Recombinant Factor VIII Treatment for Hemophilia
Greengene F
Greengene F is a third-generation gene recombination therapy for hemophilia A, which was successfully developed by GC Biopharma for the third time in the world, and excellent technological prowess and know-how of GC Biopharma are integrated in this product.P hase 3 clinical trials have been completed in China, and product approval has been obtained in 2021. GC Biopharma is also striving to develop next-generation hemophilia treatments that can treat not only patients with hemophilia A and B but also antibody-producing patients by targeting novel blood coagulation mechanisms. The company will expand its pipelines of blood disorder treatments to expand the domestic market and further increase its global market share by making inroads into the ROW market.
World-Class Quality
Plasma Derivatives
GC Biopharma remains committed to improving the products that have already won government and market approval, continuing to improve quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is enjoying growing demand in South America and elsewhere. Currently under Phase 3 clinical trial in the United States, the product is expected to be launched on the American market in a few years.
A Pioneer in the Global Vaccine Market
Oncology, Immunology, and Cell Therapy
GC Biopharma succeeded in developing Neulapeg, a treatment for neutropenia, in 2014. Designed as a supplement for immunosuppressant chemotherapy and thereby minimizing the treatment’s side effects, Neulapeg offers a longer half-life than its first-generation product. It has also enabled the Korean medical community to cease importing similar drugs from overseas. In addition, GC Biopharma is working on introducing an innovative antibody production technology. The company continues to research and develop new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.
Restoring Hope to People
with Rare Diseases
Rare Disease Treatments
The trivalent flu vaccine of GC Biopharma obtained WHO PQ (prequalification) certification, which is required to take part in international bidding, for the first time in Asia and fourth time in the world. The quadrivalent flu vaccine, GCflu Quadrivalent (approved in 2015), has added one type of influenza B virus strain to trivalent influenza vaccines to broaden the range of prophylactic vaccination and obtained WHO PQ certification for the first time in South Korea and second time in the world. Furthermore, GC Biopharma launched a Td vaccine (tetanus-diphtheria vaccine, approved in 2016) with local technologies for the first time and is now striving to develop a new combined vaccine (Tdap) that protects against all three infections–tetanus, diphtheria and pertussis. As such, GC Biopharma has a rich pipeline of vaccines against diverse diseases and will continue to make an effort to meet international standards to strengthen its global presence, going beyond domestic approval.
Future Strategy
GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Biopharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.
-
- Pharmaceutical
- GC Cell
- GCMS
- GC Wellbeing
-
- Overseas
- GC China
- GC China Pharm
- GC LabTech
-
- Overseas
- Curevo
-
- Foundation
- MOGAM Institue
- GC Labs
- GC i-Med
-
- Others
- GCEM
- GC Invacfarm